Travere Therapeutics (NASDAQ:TVTX) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Travere Therapeutics (NASDAQ:TVTX) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

TVTX has been the subject of several other reports. Wells Fargo & Company increased their target price on Travere Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group increased their target price on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Citigroup increased their target price on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. dropped their target price on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Finally, Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a research report on Tuesday, April 14th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.83.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $42.60 on Friday. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. The company has a market capitalization of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13. Travere Therapeutics has a 12 month low of $13.88 and a 12 month high of $48.61. The stock has a 50-day moving average price of $32.83 and a two-hundred day moving average price of $32.94.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.29. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business’s quarterly revenue was up 55.6% on a year-over-year basis. During the same period last year, the company earned ($0.47) earnings per share. Analysts expect that Travere Therapeutics will post -0.26 EPS for the current year.

Insider Activity at Travere Therapeutics

In other news, CEO Eric M. Dube sold 64,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $41.09, for a total transaction of $2,629,760.00. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at $17,787,285.74. This trade represents a 12.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jula Inrig sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $45.00, for a total value of $900,000.00. Following the transaction, the insider owned 111,473 shares of the company’s stock, valued at $5,016,285. This trade represents a 15.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 400,015 shares of company stock valued at $15,895,428 over the last ninety days. Insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after acquiring an additional 6,831 shares during the last quarter. Norges Bank acquired a new stake in Travere Therapeutics during the second quarter worth approximately $1,051,000. First Trust Advisors LP acquired a new stake in Travere Therapeutics during the second quarter worth approximately $3,538,000. Cresset Asset Management LLC grew its stake in Travere Therapeutics by 26.5% during the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after purchasing an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd grew its stake in Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the period.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.